Assembly Biosciences, Inc. (ASMB) Key Metrics
ASMB valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $409.0M
- Enterprise value
- $200.2M
- P/E (TTM)
- 19.3
- Forward P/E
- 500.0
- PEG ratio
- —
- Price / sales
- 5.5 10-yr median 5.3
- Price / book
- 1.7 10-yr median 1.8
- EV / EBITDA
- 0.4
- Dividend yield
- —
- Beta
- 1.16
ASMB key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsASMB valuation Price multiples at each fiscal year-end price.
ASMB returns How much profit the business earns on the capital it uses.
ASMB per-share figures Results divided by the shares outstanding at year-end.
ASMB financial health Debt, liquidity and how easily interest is covered.
ASMB efficiency & capital use Working capital cycle and where the cash goes.
ASMB valuation history
ASMB returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
ASMB debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
ASMB price vs earnings per share
ASMB key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $381.3M | $94.8M | $45.0M | — | — | — | — | — | — | — |
| Enterprise value | $135.8M | −$14.2M | −$82.9M | — | — | — | — | — | — | — |
| Price / sales | 5.3 | 3.3 | 6.3 | — | — | — | — | — | — | — |
| Price / book | 1.8 | 2.8 | 1.1 | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | 2.0 | — | — | — | — | — | — | — |
| Price / operating cash flow | — | — | 2.0 | — | — | — | — | — | — | — |
| EV / sales | 1.9 | -0.5 | -11.6 | — | — | — | — | — | — | — |
| Earnings yield | −1.6% | −42.4% | −135.9% | — | — | — | — | — | — | — |
| Free cash flow yield | −10.8% | −54.0% | 49.9% | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $34.01 | $15.78 | $9.84 | $15.60 | $27.96 | $72.60 | $245.52 | $271.44 | $543.00 | $145.80 |
| Per share | ||||||||||
| Revenue per share | $6.45 | $4.75 | $1.56 | — | — | — | — | — | — | — |
| Earnings per share | −$0.55 | −$6.69 | −$13.38 | — | — | — | — | — | — | — |
| Operating cash flow per share | −$3.67 | −$8.51 | $4.97 | — | — | — | — | — | — | — |
| Free cash flow per share | −$3.67 | −$8.52 | $4.91 | — | — | — | — | — | — | — |
| Cash per share | $22.13 | $18.67 | $28.45 | — | — | — | — | — | — | — |
| Book value per share | $18.44 | $5.56 | $8.98 | — | — | — | — | — | — | — |
| Tangible book value per share | $18.44 | $5.56 | $8.98 | — | — | — | — | — | — | — |
| Capex per share | $0.01 | $0.00 | $0.06 | — | — | — | — | — | — | — |
| Debt per share | $0.23 | $0.51 | $0.51 | — | — | — | — | — | — | — |
| Shares outstanding | 11.2M | 6.0M | 4.6M | — | — | — | — | — | — | — |
| Change in shares outstanding | +86.7% | +31.2% | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −5.1% | −107.9% | −98.9% | −73.2% | −63.4% | −24.2% | −40.4% | −56.1% | −44.4% | −44.6% |
| Return on invested capital (ROIC) | — | — | — | — | −332.4% | −223.8% | — | — | — | −91.7% |
| Return on assets (ROA) | −3.2% | −31.4% | −51.3% | −62.9% | −54.8% | −19.7% | −31.7% | −41.5% | −32.0% | −38.2% |
| Return on tangible assets | −2.4% | −33.7% | −44.7% | −90.4% | −68.0% | −25.7% | −31.9% | −40.1% | −33.5% | −78.4% |
| Free cash flow margin | −56.9% | −179.3% | 313.9% | — | — | −82.4% | −536.4% | −441.1% | 11.0% | — |
| Financial health | ||||||||||
| Total debt | $2.6M | $3.1M | $2.3M | $3.5M | $6.5M | $10.1M | $12.3M | — | $0 | $0 |
| Cash & short-term investments | $248.1M | $112.1M | $130.2M | $91.6M | $146.6M | $216.4M | $274.0M | $218.1M | $119.9M | $53.0M |
| Net debt | −$245.5M | −$109.0M | −$127.9M | −$88.1M | −$140.2M | −$206.3M | −$261.8M | −$218.1M | −$119.9M | −$53.0M |
| Debt / equity | 0.01 | 0.09 | 0.06 | 0.04 | 0.04 | 0.04 | 0.04 | — | 0.00 | 0.00 |
| Debt / assets | 0.01 | 0.03 | 0.02 | 0.03 | 0.03 | 0.04 | 0.04 | — | 0.00 | 0.00 |
| Current ratio | 5.22 | 2.42 | 3.41 | 5.95 | 9.59 | 9.19 | 11.57 | 12.05 | 9.13 | 7.52 |
| Quick ratio | 5.22 | 2.42 | 3.49 | 5.95 | 9.59 | 9.19 | 11.57 | 12.05 | 9.13 | 7.52 |
| Interest coverage | — | — | — | -189.0 | -1.6 | -24.7 | -21.4 | — | — | — |
| Working capital | $205.8M | $67.7M | $94.6M | $80.7M | $138.1M | $200.1M | $258.3M | $204.0M | $109.6M | $46.5M |
| Invested capital | −$38.7M | −$75.6M | −$86.8M | −$5.5M | $28.8M | $34.3M | $11.4M | −$7.4M | −$6.8M | $26.9M |
| Tangible asset value | $206.8M | $33.4M | $41.1M | $82.7M | $168.9M | $198.9M | $231.6M | $169.0M | $71.5M | $38.2M |
| Net current asset value | $203.7M | $29.7M | $38.1M | $77.8M | $132.1M | $181.8M | $208.1M | $165.1M | $66.9M | $35.3M |
| Graham net-net per share | $17.66 | $4.42 | $7.20 | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | — | — | — | — | $0 | $0 |
| Share buybacks (net) | — | — | — | $0 | — | $0 | $0 | $0 | $0 | $0 |
| Dividends + buybacks / free cash flow | — | — | — | — | — | — | — | — | 0.0% | — |
| Capex / revenue | 0.1% | 0.1% | 3.6% | — | 49.5% | 2.8% | 9.7% | 2.3% | 9.6% | — |
| Capex / operating cash flow | — | — | 1.1% | — | — | — | — | — | 46.5% | — |
| Capex / depreciation | 0.51 | 0.22 | 0.57 | 0.20 | 6.64 | 3.21 | 3.15 | 0.53 | 3.94 | 1.82 |
| Stock-based compensation / revenue | 6.5% | 10.9% | 71.5% | — | 83.7% | 27.6% | 128.8% | 192.4% | 95.4% | — |
| R&D / revenue | 89.6% | 196.1% | 682.7% | — | 1,095.7% | 135.0% | 537.2% | 491.4% | 490.4% | — |
| SG&A / revenue | 27.1% | 63.1% | 319.8% | — | 460.2% | 46.6% | 206.2% | 235.1% | 188.7% | — |
| Efficiency | ||||||||||
| Days sales outstanding | 3.5 | 2.8 | 25.1 | — | 45.7 | 10.6 | 66.4 | 58.0 | 92.0 | — |
| Days of inventory on hand | — | — | -11.9 | 0.0 | 0.0 | — | — | 0.0 | 0.0 | — |
| Days payables outstanding | 2,484.3 | 3.4 | 11.0 | 1,888.0 | 2,842.1 | 11.4 | 11.5 | 14.6 | 18.5 | 8,486.6 |
| Cash conversion cycle (days) | -2,480.8 | -0.6 | 2.2 | — | -2,796.4 | -0.8 | 54.8 | 43.4 | 73.5 | — |
| Receivables turnover | 105.24 | 128.76 | 14.51 | 0.00 | 7.99 | 34.36 | 5.50 | 6.29 | 3.97 | — |
| Payables turnover | 0.15 | 106.95 | 33.11 | 0.19 | 0.13 | 32.02 | 31.62 | 25.01 | 19.69 | 0.04 |
| Inventory turnover | — | — | — | 498,000.00 | 932,000.00 | — | — | 72,741,000.00 | 88,450,000.00 | — |
| Asset turnover | 0.38 | 0.22 | 0.06 | 0.00 | 0.03 | 0.25 | 0.05 | 0.07 | 0.07 | 0.00 |
| Average receivables | $687,000 | $221,500 | $493,500 | $640,000 | $783,000 | $2.3M | $2.9M | $2.4M | $2.3M | — |
| Average payables | $878,000 | $523,000 | $1.5M | $2.6M | $3.6M | $3.2M | $2.7M | $2.9M | $2.2M | $1.9M |
| Average inventory | — | — | −$1.6M | $1 | $0 | $0 | $0 | $1 | $0 | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 14.7% | 12.0% | 15.5% | 24.6% | 42.4% |
Computed from ASMB's annual financial statements (latest annual report filed March 19, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
ASMB valuation and financial ratios
Based on the latest twelve months, the trailing P/E is 19.3 and the forward P/E is 500.0. Assembly Biosciences earned a return on equity of −5.1% in fiscal 2025. It ended the year with $2.6 million of debt and $248.1 million in cash and short-term investments, a net cash position of $245.5 million.
See the ASMB income statement, the ASMB chart for price history, or the ASMB stock overview for the latest quote and news.
ASMB key metrics FAQ
What is Assembly Biosciences's P/E ratio?
Assembly Biosciences's trailing P/E ratio is 19.3 based on the last twelve months of earnings (as of October 17, 2026), and its forward P/E is 500.0. At the end of fiscal 2025 it was —.
What is Assembly Biosciences's return on equity?
Assembly Biosciences's return on equity (ROE) was −5.1% in fiscal 2025: net income of -$6.1 million on average shareholders' equity of $120.1 million.
How much debt does Assembly Biosciences have?
Assembly Biosciences had total debt of $2.6 million at the end of fiscal 2025, a debt-to-equity ratio of 0.01 and more cash than debt.
What is Assembly Biosciences's free cash flow yield?
Assembly Biosciences generated -$41.2 million of free cash flow in fiscal 2025, a free cash flow yield of −10.8% on its market value at year-end ($381.3 million).
What is Assembly Biosciences's current ratio?
Assembly Biosciences's current ratio was 5.22 at the end of fiscal 2025: current assets were 5.22 times current liabilities.